NASDAQ:ONC BeOne Medicines Q1 2025 Earnings Report $360.15 +12.67 (+3.65%) As of 12:16 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast BeOne Medicines EPS ResultsActual EPS$1.22Consensus EPS -$0.71Beat/MissBeat by +$1.93One Year Ago EPSN/ABeOne Medicines Revenue ResultsActual Revenue$1.12 billionExpected Revenue$1.12 billionBeat/MissMissed by -$7.30 millionYoY Revenue GrowthN/ABeOne Medicines Announcement DetailsQuarterQ1 2025Date5/7/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile BeOne Medicines Earnings HeadlinesBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Given Average Rating of "Buy" by AnalystsAugust 17 at 3:44 AM | americanbankingnews.comJohn Oyler Sells 115,011 Shares of BeOne Medicines (NASDAQ:ONC) StockAugust 14 at 4:09 AM | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 17 at 1:00 AM | Chaikin Analytics (Ad)John Oyler Sells 70,907 Shares of BeOne Medicines (NASDAQ:ONC) StockAugust 14 at 4:09 AM | americanbankingnews.comJohn Oyler Sells 54,892 Shares of BeOne Medicines (NASDAQ:ONC) StockAugust 14 at 4:09 AM | americanbankingnews.comUBS Keeps Their Buy Rating on BeOne Medicines Ltd (6160)August 13, 2026 | theglobeandmail.comSee More BeOne Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email. Email Address About BeOne MedicinesBeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.View BeOne Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 5 Dividend Stocks Show Why Income Investing Still MattersThe Quantum Race Is Heating Up—And 2 Small Players Stand OutMarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsLooking Beyond CrowdStrike? 3 AI Security Stocks Stand Out5 Recession-Proof Stocks Hiding in Cardboard BoxesBack From Orbit, Intuitive Machines' Share Price Enters the Buy Zone Upcoming Earnings Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
